2096 — Simcere Pharmaceutical Share News
0.000.00%
Last trade - 00:00- HK$27.27bn
- HK$24.00bn
- CNY7.73bn
Brief: Simcere Pharmaceutical Says Hypnotics Daridorexant Hydrochloride Obtained Clinical Trial Approval
Brief: Simcere Pharmaceutical Says New Drug Application Of Sanbexin Sublingual Tablets Accepted By NMPA
China's Simcere Pharmaceutical jumps most in 5 months on share buyback plan
Brief: Simcere Pharmaceutical Resolves To Utilize Repurchase Mandate In Open Market
Brief: Simcere Pharmaceutical Group Announces Sponsored Research Agreement With Mass General Brigham
Brief: Simcere Pharmaceutical Says Sanbexin Got Clinical Trial Approval Issued By NMPA
Brief: Simcere Pharmaceutical Posts Profit For Year Attributable RMB933 Million
Brief: Simcere Zaiming Announces Clinical Collaboration To Evaluate SIM0235 In Phase 1 Trial
Brief: Simcere Pharmaceutical Sees Revenue Of RMB6,289 Mln To RMB6,349 Mln For FY2022
Brief: Simcere Pharmaceutical Announce Issuance Of First Prescription For COSELA(Trilaciclib) In China
China approves two domestically developed COVID drugs
Brief: Ascletis Pharma Announces A Supply Agreement Of Ritonavir Tablets With Simcere Pharmaceutical
Brief: Simcere Pharmaceutical Says New Drug Application Of Anti-Sars-Cov-2 Accepted By NMPA
HK-listed Simcere Pharma up on obtaining China's clinical trial approval for product
Brief: Simcere Pharmaceutical Got Clinical Trial Approval For Sim0237 Issued By NMPA
Brief: Simcere Pharmaceutical Resolved To Propose To Appoint Wang Xi An Executive Director
Brief: Phase II/III Clinical Trial Of Simcere's XIANNUOXIN Completes Patients Enrollment
Brief: Simcere Pharmaceutical Says Phase 3 Study Of Sanbexin Sublingual Tablets Got Efficacy Endpoints
Brief: Simcere Pharmaceutical Announces Exclusive License Deal With Idorsia For Insomnia Drug